Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 71, Issue 8, Pages 1877-1887Publisher
SPRINGER
DOI: 10.1007/s00262-021-03124-x
Keywords
Photoimmunotherapy; mEERL; Panitumumab; Cetuximab; Epidermal growth factor receptor
Categories
Funding
- Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research [ZIA BC011513]
- National Center for Global Health and Medicine Research Institute, Tokyo, Japan
Ask authors/readers for more resources
This study compared the effects of Panitumumab and Cetuximab in APCs for NIR-PIT and the impact of different light exposure regimens on tumor growth in an immunocompetent mouse model. The results showed that APCs with longer half-life and double light exposure had superior outcomes in cancer cell-targeted NIR-PIT.
Near-infrared photoimmunotherapy (NIR-PIT) is a cell-specific cancer therapy that uses an antibody-photoabsorber (IRDye700DX, IR700) conjugate (APC) and NIR light. Intravenously injected APC binds the target cells, and subsequent NIR light exposure induces immunogenic cell death only in targeted cells. Panitumumab and cetuximab are antibodies that target human epidermal growth factor receptor (hEGFR) and are suitable for NIR-PIT. In athymic nude mouse models, panitumumab-based NIR-PIT showed superior therapeutic efficacy compared to cetuximab-based NIR-PIT because of the longer half-life of panitumumab-IR700 (pan-IR700) compared with cetuximab-IR700 (cet-IR700). Two light exposures on two consecutive days have also been shown to induce superior effects compared to a single light exposure in the athymic nude mouse model. However, the optimal regimen has not been assessed in immunocompetent mice. In this study, we compared panitumumab and cetuximab in APCs for NIR-PIT, and single and double light exposures using a newly established hEGFR-expressing cancer cell line derived from immunocompetent C57BL/6 mice (mEERL-hEGFR cell line). Fluorescence imaging showed that the decline of pan-IR700 was slower than cet-IR700 confirming a longer clearance time. Among all the combinations tested, mice receiving pan-IR700 and double light exposure showed the greatest tumor growth inhibition. This group was also shown to activate CD8(+) T lymphocytes in lymph nodes and accumulate CD8(+) T lymphocytes to a greater extent within the tumor compared with the control group. These results showed that APCs with longer half-life and double light exposure lead to superior outcomes in cancer cell-targeted NIR-PIT in an immunocompetent mouse model.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available